Abstract:BackgroundWhile the frequency and importance of antipsychotic switching in patients with schizophrenia, there is insufficient evidence with regard to switching strategy. Quetiapine is one of the drugs of choice for switch because of its unique receptor profile. However, there were no data on the long-term clinical and neurocognitive effect of quetiapine in patients who had responded inadequately to prior antipsychotics. The purpose of this study is to examine the long-term efficacy and tolerability of quetiapine in patients with schizophrenia who switched from other antipsychotics because of inadequate therapeutic response. We hypothesized that quetiapine would show long-term effectiveness in broad symptom dimensions including negative and neurocognitive symptoms while having good tolerability.MethodsTwenty-nine subjects with schizophrenia who did not respond to their current monotherapy of antipsychotic or who could not tolerate the treatment were switched to quetiapine and assessed at baseline and at 3, 6, and 12 months. The outcome measures included the brief assessment of cognition in schizophrenia (BACS), the Positive and Negative Syndrome Scale (PANSS), the Clinical Global Impressions Scale (CGI), the Schizophrenia Quality of Life Scale Japanese version (JSQLS), the Athens Insomnia Scale (AIS), and the Drug Attitude Inventory with 30 items (DAI-30). The Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS), HbA1c, prolactin (PRL), and body weight were also evaluated.ResultsStatistically significant improvements were observed in all subscores of the PANSS, the GAF, and the symptoms and side effects subscale of the JSQLS, the DIEPSS, the AIS, and the PRL level, and nearly significant improvements were observed in the DAI-30. Quetiapine monotherapy was associated with significant improvement in the verbal memory test, even after controlling for the practice effect. Although quetiapine was well tolerated, three subjects dropped out because of the worsening of the psychotic symptoms and two additional subjects dropped out because of somnolence.ConclusionIn this open-label, single-arm study of 29 patients, quetiapine improved both the clinical symptoms and the neurocognitive impairment in chronic schizophrenia patients who failed to respond to prior antipsychotic treatment.

A One-Year Follow-Up Study of 33 Female Schizophrenic Patients with Menstrual Disturbances after Switching to Quetiapine

Efficacy and Safety of Quetiapine Extended Release Monotherapy in Bipolar Depression: a Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial

The Impact of Quetiapine Monotherapy or in Combination with Lithium on the Thyroid Function in Patients with Bipolar Depression: A Retrospective Study

Long-term efficacy and tolerability of quetiapine in patients with schizophrenia who switched from other antipsychotics because of inadequate therapeutic response—a prospective open-label study

Efficacy of Quetiapine Monotherapy and Combination Therapy for Patients with Bipolar Depression with Mixed Features: A Randomized Controlled Pilot Study

Lurasidone Versus Quetiapine for Cognitive Impairments in Young Patients with Bipolar Depression: A Randomized, Controlled Study

Clinical study of quetiapine and clozapine in the treatment of schizophrenia

Response and Remission Rates in Chinese Patients with Bipolar Mania Treated for 4 Weeks with Either Quetiapine or Lithium: a Randomized and Double-Blind Study.

Randomized controlled 16-week trial of the effect of quetiapine on the quality of life and cognitive functioning of patients in acute episodes of schizophrenia

A Study on the Changes of Prolaction Levels of Female Patients with Schizophrenia after the Treatment of Aripiprazone, Ziprasidone and Risperidone

Quetiapine and risperdal in the treatment of schizophrenia:an one-year follow up study.

The Effects of Antipsychotics on Serum Prolactin in the First-Episode Schizophrenia Patients

Efficacy and Safety of Quetiapine in the Treatment of Bipolar Acute Mania: a Randomized, Double-Blind, Lithium-Controlled Multicenter Study

Efficacy and safety of aripiprazole and quetiapine in the treatment of schizophrenia

Efficacy and safety of aripiprazole and quetiapine in treatment of schizophrenia

Multi-center, double blind control study of domestic manufactured quetiapine on schizophrenia

A 6-Week, Multicenter, Double-Blind, Double-Dummy, Chlorpromazine-Controlled Non-Inferiorityrandomized Phase Iiitrial to Evaluate the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended-Release (XR) in the Treatment of Patients with Schizophrenia and Acute Episodes.

A Comparison Study on Efficacy and Safety of Quetiapine and Chlorpromazine in the Treatment of Schizophrenia

Role of Quetiapine Combined with Modified Electroconvulsive Therapy in Bipolar Depression

Efficacy of Repetitive Transcranial Magnetic Stimulation with Quetiapine in Treating Bipolar II Depression: a Randomized, Double-Blinded, Control Study

Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study